# Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)

> **NCT00684567** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00684567
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-27
- **Primary completion:** 2007-10-31
- **Final completion:** 2007-10-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684567, "Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00684567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*